Quick Dispatch:
Your tirzepatide surmount trials EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount trials EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients ships.
Need Help?
Questions about tirzepatide surmount trials EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount trials EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients in your area.
Sound Weight Loss | The SURMOUNT-5 trial just confirmed it: tirzepatide outperformed semaglutide 20.2% vs 13.7% weight loss over 72 weeks. That is nearly 50%
23.28
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
25.80
Tirzepatide not linked to increased risk for depression
21.63
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
21.42
00377-2/asset/984f48c3-9a91-4eba-8a7d-d724f5e65288/main.assets/gr2_lrg.jpg)
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
22.22
Tirzepatide Demonstrates Sustained Weight Loss but Discontinuation Results in Weight Regain: SURMOUNT-4 Trial
19.99
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
26.95
